2022 Archive

Read and Download 2022 Reports

Learn about new approvals and the state of the field for each quarter of 2022.

Q4 2022

In Q4, gene therapies Hemgenix and Adstiladrin were approved in the U.S. for hemophilia B and bladder cancer, respectively.

Q3 2022

In Q3, there were two new gene therapy approvals and three new RNA vaccine approvals, increases in dealmaking and fundraising, and development on anticancer indications within non-genetically modified cell therapy. 

Q2 2022

This quarter, a gene therapy for epidermolysis bullosa awaits approval in the U.S. and a CAR T-cell therapy for multiple myeloma awaits approval in China.

Q1 2022

Highlights include approval of a CAR T-cell therapy for multiple myeloma in the U.S., filing for approval of an AAV5 gene therapy for hemophilia B in the EU and the UK, and more.


Register for the 27th Annual Meeting

May 7-11, 2024 | Baltimore, MD

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.